Clinical Trials Logo

Pain, Neuropathic clinical trials

View clinical trials related to Pain, Neuropathic.

Filter by:

NCT ID: NCT04375436 Completed - Pain, Neuropathic Clinical Trials

Safety and Tolerability of NTRX-07 in Healthy Volunteers

Start date: October 10, 2019
Phase: Phase 1
Study type: Interventional

Randomized, placebo-controlled, modified parallel-design single ascending dose (SAD) in adult healthy volunteers (HVs).

NCT ID: NCT04371575 Completed - Multiple Sclerosis Clinical Trials

Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients

Start date: September 1, 2012
Phase:
Study type: Observational

Clinical characteristics, neuroanatomical findings and efficacy of medical and surgical treatment of symptomatic trigeminal neuralgia - a systematic prospective study of 60 consecutive patients

NCT ID: NCT04299893 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

O3NPIQ
Start date: November 30, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy

NCT ID: NCT04235478 Active, not recruiting - Pain, Neuropathic Clinical Trials

Effect of the Cervical Interlaminar Epidural Steroid Injection on Quality of Life, Pain and Disability

Start date: December 27, 2017
Phase: N/A
Study type: Interventional

To evaluate the effect of cervical interlaminar epidural steroid injections on the neuropathic pain, quality of life and disability patients with cervical radiculopathy. After the clinical and MRG evaluations of patients with neck and arm pain, injection was given to eligible patients. Patients undergone the procedure were evaluated before and after injection for neuropathic pain, quality of life and disability.

NCT ID: NCT04204668 Enrolling by invitation - Phantom Limb Pain Clinical Trials

Surgical Treatments for Neuroma Pain in Amputees

STOCAP
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Amputees often suffer from relentless pain and disability resulting from symptomatic neuromas within the amputation stumps. When conservative measures fail to address these symptoms, two contemporary surgical approaches to treat symptomatic neuromas have become the most popular. Targeted muscle reinnervation (TMR) is a procedure which involves transferring the injured proximal nerve stump into a terminal nerve branch entering muscle, such that the axons from the proximal nerve stump will regenerate into the muscle and thereby prevent neuroma recurrence. Regenerative peripheral nerve interfaces (RPNIs) are muscle grafts placed on the proximal nerve stumps that serve as targets for the regenerating axons from the proximal nerve stumps. While TMR and RPNIs have demonstrated promise for the treatment of symptomatic neuromas, prospective comparative data comparing outcomes with these two approaches is lacking. The investigators have recently developed a novel approach to treat symptomatic neuromas that provides vascularized, denervated muscle targets (VDMTs) for the axons regenerating from the severed proximal nerve stump to reinnervate. This is accomplished by islandizing a segment of muscle on its blood supply and ensuring complete denervation prior to implanting the neighboring transected nerve stump into this muscle. VDMTs offer theoretical benefits in comparison to RPNIs and TMR that the investigators also aim to test in the proposed study. The investigators' objective is to enroll amputees with symptomatic neuromas into a prospective study in which amputees will be randomized to undergo TMR, RPNI, or VDMT and subsequently monitored for pain and disability for 1-year post-operatively. The investigators' specific aims are as follows: 1) Test the hypothesis that VDMTs are more effective than TMR and RPNIs with regards to treating pain and disability associated with symptomatic neuromas; 2) Provide the first level one, prospective data directly comparing the efficacy of TMR and RPNIs.

NCT ID: NCT04196686 Completed - Pain, Acute Clinical Trials

Ice Immersion Using Virtual Reality & Augmented Reality

Start date: July 24, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of different technologies, Virtual Reality and Augmented Reality with modifications as passive content, active content, cognitive load modulation, and positive encouragement coaching to increase the pain threshold as assessed by immersing a hand in ice water.

NCT ID: NCT04097015 Enrolling by invitation - Clinical trials for Spinal Cord Injuries

Using NI-ES to Treat Spinal Cord Injury (SCI)

Start date: September 20, 2019
Phase: N/A
Study type: Interventional

NI-ES therapy is a treatment that is being studied to potentially treat pain associated with SCI and may help movement below the injury site.

NCT ID: NCT04080037 Completed - Pain Clinical Trials

Assessing Opioid Care Practices Using CPV Patient Simulation Modules

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback. The cases and feedback have been designed to align with the latest CDC opioid guidelines. The study will also measure the impact of gaming-inspired competition and motivation, including a weekly leaderboard, to improve evidence-based care decisions. The quality of care decisions will be measured in the simulations and in a multiple-choice assessment administered before and after the patient simulations.

NCT ID: NCT03928093 Completed - Pain, Neuropathic Clinical Trials

Pregabalin Treatment for RDEB Pain and Itch

Start date: August 7, 2019
Phase: Phase 3
Study type: Interventional

Recessive dystrophic epidermolysis bullosa (RDEB) patients' quality of life is severely affected by neuropathic pain and itch, which have recently been demonstrated to be secondary to skin small fiber neuropathy. To date, there is no evidence on what the best agent is to control these symptoms. Based on the anecdotal data and safety profile, the investigators believe that pregabalin is a therapeutic agent that will be effective and safe in this population. The investigators propose to conduct a blinded study, using pregabalin versus placebo in which each patient serves as its own control (cross-over design). This is a feasibility study that will provide preliminary data on efficacy and safety of pregabalin in RDEB patients with neuropathic pain and itch and gather much needed data (dosage, titration schedule, outcome measures, etc) to inform the design of a larger cohort, controlled, multicenter trial.

NCT ID: NCT03865693 Recruiting - Pain, Neuropathic Clinical Trials

Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Prevalence of chronic pain has been shown to be high after thermal injury. Post-burn neuropathic pain causes chronic disabilities that is often difficult to treat effectively. Pain Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device. To study changes in the pain network associated with neuropathic pain, magnetic resonance imaging(MRI) was used to evaluate cerebral blood volume(CBV) in patients who had been injuried by burn. Participants (N=40, experimental 20 and control group 20) comprised patients with neuropathic pain after thermal injury. The subjects complained of severe neuropathic pain that was rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities. Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort. The intensity of neuropathic pain was measured using the visual analogue scale(VAS). Depressive mood was assessed using the Beck Depression Scale. Voxel-wise comparisons of relative CBV maps were made between before scrambler therapy and after 10 scrambler therapy sessions over the entire brain volume. The relationship between individual participant CBV(measured in voxels), BDS and VAS score was also examined. We observed decreased in the cerebral pain network of patients with burn injury. Scrambler therapy is a non-invasive, non-medicinal modality that significantly reduced burn-associated neuropathic pain. Scrambler therapy should be considered as a treatment option for burn survivors with severe neuropathic pain.